Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc. develops medical devices for treating cancer and infectious disease disorders. The company focuses on extracorporeal blood purification. For cancer treatment, Sigyn Therapeutics created the ImmunePrep TM platform to enhance immunotherapeutic antibodies, ChemoPrep TM to improve chemotherapy delivery, and ChemoPure TM to reduce chemotherapy toxicity. The company's primary therapeutic candidate is Sigyn Therapy TM, designed to address infectious disease disorders that are not treatable with drugs. Sigyn Therapy TM works by extracting pathogens and toxins from a patient's bloodstream and dampening excessive immune responses linked to life-threatening infections. This therapy has been validated to extract viral pathogens, bacterial toxins (including endotoxin), hepatic toxins, and inflammatory cytokines from human blood plasma. Sigyn Therapy TM aims to address several global health needs: untreatable viral pathogens (over 200 viruses that infect humans are not treatable with drugs), antibiotic-resistant bacterial infections, endotoxemia (a bacterial toxin that commonly induces sepsis), and sepsis (a leading cause of hospital deaths in the United States). The company's team has prior experience developing blood purification technologies, including a medical device that received FDA "Emergency Use Authorization" for Ebola and two "Breakthrough Device" designations from the FDA.